AbbVie Fights Evidence Ahead Of Testosterone Bellwether
As a first bellwether trial over the alleged health risks of testosterone therapy AndroGel approaches, drugmaker AbbVie and consumers agree that the trial shouldn't be split into two phases, but AbbVie...To view the full article, register now.
Already a subscriber? Click here to view full article